19 August 2021 | News
To enable the development of a partnership aimed at combining 3D biology
image credit- shutterstock
France-based biotech startup HCS Pharma is entering into incubation at the prestigious NHRI (National Health Research Institutes) in Taiwan. There, it will develop collaborations to put its exclusive BIOMIMESYS® technology at the service of the country's four major scientific research institutions. HCS Pharma has also opened a representative office in Taiwan, headed by Joseph Chou.
It will also enable the development of a partnership aimed at combining 3D biology, the use of semiconductors for real-time cell analysis, and microfluidics to create the first 3D "organ-like" biochip for drug discovery.
After several years of research, HCS Pharma has brought to the drug discovery market its unique BIOMIMESYS® technology, which allows for the simple implementation of 3D in vitro tests in conditions close to those of the human body organs. In vitro tests are a critical step in the development of new drugs. They allow the validation of a molecule's efficacy and safety well before the costly phases of clinical testing.
This presence in Taiwan will also strengthen current collaborations with the three other major national research institutions: Academia Sinica, Industrial Technology Research Institute (ITRI), Development Center for Biotechnology (DCB).